Two distinct combinations of NEC-driving factors—RB1 knockout, TP53 R175H, N-MYC, with either ASCL1 or NeuroD1 (designated as RPMA or RPMN, respectively)—were employed. This evidence concerns the gene ASCL1 and neuroendocrine carcinoma.